全文获取类型
收费全文 | 4399篇 |
免费 | 374篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 30篇 |
儿科学 | 201篇 |
妇产科学 | 131篇 |
基础医学 | 672篇 |
口腔科学 | 92篇 |
临床医学 | 421篇 |
内科学 | 913篇 |
皮肤病学 | 88篇 |
神经病学 | 326篇 |
特种医学 | 564篇 |
外科学 | 651篇 |
综合类 | 60篇 |
一般理论 | 3篇 |
预防医学 | 205篇 |
眼科学 | 110篇 |
药学 | 171篇 |
中国医学 | 3篇 |
肿瘤学 | 156篇 |
出版年
2021年 | 40篇 |
2018年 | 48篇 |
2017年 | 35篇 |
2016年 | 45篇 |
2015年 | 64篇 |
2014年 | 72篇 |
2013年 | 105篇 |
2012年 | 103篇 |
2011年 | 105篇 |
2010年 | 118篇 |
2009年 | 96篇 |
2008年 | 113篇 |
2007年 | 114篇 |
2006年 | 143篇 |
2005年 | 121篇 |
2004年 | 123篇 |
2003年 | 113篇 |
2002年 | 118篇 |
2001年 | 106篇 |
2000年 | 120篇 |
1999年 | 104篇 |
1998年 | 152篇 |
1997年 | 134篇 |
1996年 | 146篇 |
1995年 | 116篇 |
1994年 | 95篇 |
1993年 | 96篇 |
1992年 | 85篇 |
1991年 | 83篇 |
1990年 | 91篇 |
1989年 | 134篇 |
1988年 | 115篇 |
1987年 | 111篇 |
1986年 | 99篇 |
1985年 | 109篇 |
1984年 | 70篇 |
1983年 | 64篇 |
1982年 | 68篇 |
1981年 | 52篇 |
1980年 | 61篇 |
1979年 | 59篇 |
1978年 | 43篇 |
1977年 | 60篇 |
1976年 | 45篇 |
1975年 | 58篇 |
1974年 | 45篇 |
1973年 | 39篇 |
1972年 | 40篇 |
1970年 | 44篇 |
1968年 | 43篇 |
排序方式: 共有4797条查询结果,搜索用时 15 毫秒
1.
Susan E. Hickman Alexia M. Torke Greg A. Sachs Rebecca L. Sudore Anne L. Myers Qing Tang Giorgos Bakoyannis Bernard J. Hammes 《Journal of pain and symptom management》2019,57(6):1143-1150.e5
ContextIt is especially important that patients are well informed when making high-stakes, preference-sensitive decisions like those on the Physician Orders for Life-Sustaining Treatment (POLST) form. However, there is currently no way to easily evaluate whether patients understand key concepts when making these important decisions.ObjectivesTo develop a POLST knowledge survey.MethodsExpert (n = 62) ratings of key POLST facts were used to select items for a POLST knowledge survey. The survey was administered to nursing facility residents (n = 97) and surrogate decision-makers (n = 112). A subset (n = 135) were re-administered the survey after a standardized advance care planning discussion to assess the scale's responsiveness to change.ResultsThe 19-item survey demonstrated adequate reliability (α = 0.72.). Residents' scores (x = 11.4, standard deviation 3.3) were significantly lower than surrogate scores (x = 14.7, standard deviation 2.5) (P < 0.001). Scores for both groups increased significantly after administration of a standardized advance care planning discussion (P < 0.001). Although being a surrogate, age, race, education, cognitive functioning, and health literacy were significantly associated with higher POLST Knowledge Survey scores in univariate analyses, only being a surrogate (P < 0.001) and being white (P = 0.028) remained significantly associated with higher scores in multivariate analyses.ConclusionThe 19-item POLST Knowledge Survey demonstrated adequate reliability and responsiveness to change. Findings suggest the survey could be used to identify knowledge deficits and provide targeted education to ensure adequate understanding of key clinical decisions when completing POLST. 相似文献
2.
Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder 总被引:1,自引:0,他引:1
G E Tesar J F Rosenbaum M H Pollack M W Otto G S Sachs J B Herman L S Cohen S A Spier 《The Journal of clinical psychiatry》1991,52(2):69-76
To test the reported antipanic efficacy of clonazepam, the authors randomized 72 subjects with panic disorder to 6 weeks of treatment with either alprazolam, clonazepam, or placebo. Endpoint analysis demonstrated a significant beneficial effect of both active treatments, but not placebo treatment, on the frequency of panic attacks, overall phobia ratings, and the extent of disability. Comparison of the two active treatments revealed no significant differences and no consistent tendency for one agent to be favored over another, although power to detect small differences was limited. Sedation and ataxia were the most common side effects reported, but these effects were mild and transient and did not interfere with treatment outcome. The results of this double-blind, placebo-controlled trial are consistent with previous reports of clonazepam's antipanic efficacy. 相似文献
3.
Practical management of patients with non-small-cell lung cancer treated with gefitinib. 总被引:7,自引:0,他引:7
Neelam T Shah Mark G Kris William Pao Leslie B Tyson Barbara M Pizzo Murk-Hein Heinemann Leah Ben-Porat Dana L Sachs Robert T Heelan Vincent A Miller 《Journal of clinical oncology》2005,23(1):165-174
PURPOSE: The use of gefitinib, the first drug approved to inhibit the epidermal growth factor receptor tyrosine kinase, is indicated in patients with non-small-cell lung cancer with tumors progressive after chemotherapy. The unique mechanism of action of this agent leads to distinctive patterns of response and toxicity in persons with lung cancer. Many of the principles of management relevant to gefitinib are distinct from those with conventional cytotoxic drugs. To meet this need, we present practical guidelines on the use of gefitinib in patients with non-small-cell lung cancer. METHODS: This article reviews gefitinib's indications, dosing, response phenomena, and patterns of relapse in individuals with radiographic response. RESULTS: We present our recommendations for the management of rash and diarrhea caused by this agent. CONCLUSION: This information can guide practitioners and help them inform their patients about what to expect when they receive gefitinib. 相似文献
4.
5.
6.
Laura L S Howe Ashton M Anderson David A S Kaufman Bonnie C Sachs David W Loring 《Archives of clinical neuropsychology》2007,22(6):753-761
We prospectively evaluated performance of 63 referrals to a memory disorders clinic who received the Medical Symptom Validity Test (MSVT) as part of their standard neuropsychological evaluation. The patients were grouped based on independent medical diagnoses and presence or absence of a potential financial incentive to under-perform. Twenty-seven patients (42.9%) scored below cutoffs on the MSVT symptom validity indices. Two individuals in the potential financial incentive group showed clear signs of invalid responding (18.2%). Twenty-two of the remaining 25 patients who failed the symptom validity indices corresponded to the dementia profile. Three individuals did not correspond to the dementia profile but are thought to have performed validly representing a 4.8% false positive rate. When considering all MSVT indices, the base rate of invalid responding in the potential financial incentive to under-perform group increased to 27.3%. Combining all groups our base rate of invalid responding was 4.8%. Specific performances are presented. 相似文献
7.
Milena G. J. Jahoda Helen Brandenburg Titia Cohen-Overbeek Frans J. Los Eva S. Sachs Juriy W. Wladimiroff 《American journal of medical genetics. Part A》1993,46(5):483-485
Data from 4,300 consecutive cases following prenatal diagnosis by transcervical (TC) CVS (n = (1,570) and transabdominal (TA) CVS (n = 2,370) were evaluated. In the follow-up study only infants examined by a physician were included. Gestational age varied between 8.5 and 11.6 weeks (mean 10.3 weeks) for TC-CVS and between 9.3 and 20 weeks (mean 12.3 weeks) for TA-CVS 98% of TC-CVS was performed at 9–10 weeks, 80.7% of TA-CVS procedures were carried out at 12–15 weeks. Selective termination took place in 97 cases of TC-CVS (6.1%) and in 72 cases of TA-CVS (2.6%). Another 8 Women had a termination for psychosocial reasons, resulting in 4,123 (1,469 TC, 2,645 TA) continuing pregnancies. The overall fetal loss rare <28 weeks was 5.4% (n = 80) for TC-CVS and 2.6% (n = 70) for TA-CVS. The overall incidence of congenital abnormalities after birth was 0.9%. Two terminal transversal limb defects were detected in the TC-CVS group (0.14%) against one (0.04%) in the TA-CVS group. © 1993 Wiley-Liss, Inc. 相似文献
8.
9.
10.
15 patients with acute myeloid leukaemia (AML) were treated with low-dose cytosine arabinoside (LD ARA-C). 2 patients had complete remissions, which lasted for 8 and 3 months, and 5 patients had a partial remission. 46% of the patients thus responded to LD ARA-C. This included 1 responding patient who had not previously responded to therapy with 6-mercaptopurine, thioguanine, or vinblastine. The 2 patients with complete remission did not show LD ARA-C-induced hypoplasia of bone marrow, although 1 had hypoplastic AML before therapy. Leukaemic cells from 1 patient showed in vivo maturation from M1 to M3 after LD ARA-C treatment. The present results, together with the published data, indicate that: a. LD ARA-C treatment, although it may have some toxic effects, is an effective treatment for some patients with AML, especially those with hypoplastic AML; b. Response to LD ARA-C can be obtained after one or several courses of treatment; c. LD ARA-C-induced remissions are sometimes obtained even in patients who fail in more conventional treatments; d. LD ARA-C-induced remissions can be achieved without bone marrow hypoplasia, and induction of hypoplasia by itself does not always result in complete remission; e. LD ARA-C can induce in vivo maturation of leukaemic cells. It is suggested that induction of remission in AML patients by LD ARA-C may result from either differentiation of leukaemic blast cells, cytotoxicity to leukaemic blasts, or both mechanisms acting together. 相似文献